Theranostics · 2012 · 79 citations · 85 references
Imaging BiomarkersEngineeringOncologic ImagingBiomedical EngineeringKey BiomarkersTumor BiologyAngiogenesisVascular ImagingTherapeutic ImagingMolecular ImagingCancer ResearchRadiologyMedical ImagingTumor GrowthVascular BiologyIntegrin ImagingTumor MicroenvironmentBiomedical ImagingMedicine
Angiogenesis drives tumor growth and is a primary target for therapy, while molecular imaging offers early diagnostic and image‑guided therapeutic opportunities. This review surveys advances in targeted imaging of integrin and VEGF‑receptor biomarkers and proposes future studies to evaluate their competitiveness for early diagnosis and image‑guided therapy. Tracers for these biomarkers have been developed across modalities, with PET integrin tracers currently in clinical trials. Longitudinal imaging in tumor models shows a complex pattern of tracer uptake, indicating drug‑induced regression followed by vascular rebound.
Angiogenesis is a fundamental requirement for tumor growth and therefore it is a primary target for anti-cancer therapy. Molecular imaging of angiogenesis may provide novel opportunities for early diagnostic and for image-guided optimization and management of therapeutic regimens. Here we reviewed the advances in targeted imaging of key biomarkers of tumor angiogenesis, integrins and receptors for vascular endothelial growth factor (VEGF). Tracers for targeted imaging of these biomarkers in different imaging modalities are now reasonably well-developed and PET tracers for integrin imaging are currently in clinical trials. Molecular imaging of longitudinal responses to anti-angiogenic therapy in model tumor systems revealed a complex pattern of changes in targeted tracer accumulation in tumor, which reflects drug-induced tumor regression followed by vascular rebound. Further work will define the competitiveness of targeted imaging of key angiogenesis markers for early diagnostic and image-guided therapy.
85
Rakesh Kumar, Victoria B. Knick, Sharon K. Rudolph et al. · Molecular Cancer Therapeutics · 2007 · 512 citations